Summary · why it matters
Caina Shares shareholders have signed an agreement with Zhejiang Paitai Pharmaceutical Industry Company Limited to transfer a total of 22.011 million shares, representing 18.01% of the total share capital, for a total consideration of 756 million yuan. This equity change will not lead to a change in the company's controlling shareholder or actual controller, and constitutes a strategic financial investment rather than a control acquisition. Paitai Pharmaceutical has committed not to reduce its shareholding within 18 months after the completion of the share transfer. The shares directly held by actual controllers Lu Jun, Lu Weiwei, and Zhao Hong are being transferred at 37.40 yuan per share, a 46.5% premium over the closing price of 25.53 yuan on July 20. Shares held by three partnerships, Weidaer, Weidafeng, and Weidayuan, are being transferred at 27.00 yuan per share. Through this transfer, the actual controllers will cash out 581 million yuan, and their combined shareholding will drop from 50.83% to 38.13%. The transferee, Paitai Pharmaceutical, is a wholly-owned subsidiary of Zhejiang Paitai Biotechnology Company Limited, established in March 2025. Its parent company has a central enterprise background, with China Resources Double-Crane Pharmaceutical Company Limited holding a 25.29% stake. As of December 31, 2025, Paitai Pharmaceutical's audited total assets were 1.641 billion yuan, net assets were 1.261 billion yuan, 2025 annual revenue was 533.54 million yuan, and net profit was 218.62 million yuan. Caina Shares has faced sustained performance pressure in recent years, with revenue declining 11.82%, 5.50%, and 8.04% year-on-year from 2023 to 2025, and net profit falling 30.46%, 52.83%, and 89.41% respectively. The introduction of a strategic industry shareholder is expected to enhance company value, but in the short term, risks such as changes in governance structure need attention.
Caina Technology Co. Ltd.
China Resources Double-Crane Pharmaceutical Co Ltd